In 2016, active surveillance has finally become standard of care for low-risk prostate cancer in the United States. Recent articles from prospective, community-based registries have shown uptake of active surveillance skyrocketing to 40% to 50% for low-risk disease in the current decade, up from rates that historically rarely exceeded 10%.1,2 A growing body of evidence indicates that active surveillance can preserve quality of life without posing substantial short- to intermediate-term oncologic risk. Based on this evidence, a recent guideline endorsed by the American Society of Clinical Oncology (ASCO) now clearly states that surveillance is not merely an option for men with low-risk disease but rather is the preferred alternative for any clinically localized, Gleason 3 + 3 cancer.3
Cooperberg MR. Active Surveillance for Low-Risk Prostate Cancer—An Evolving International Standard of Care. JAMA Oncol. 2017;3(10):1398–1399. doi:10.1001/jamaoncol.2016.3179
Customize your JAMA Network experience by selecting one or more topics from the list below.